The partners believe their technology could have advantages over others used in early-stage cancer detection, such as next-generation sequencing.
The funding will be directed at conducting clinical trials for its technology based on activity sensors to detect human diseases and monitor drug responses.
The method uses graphene-coated silica particles fused to complementary RNA to register impedance changes in the presence of viruses.
